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SERUM CONCENTRATIONS FOLLOWING FIVE TREATMENT
SCHEDULES WITH PROCAINE PENICILLIN IN OIL
WITH ALUMINUM MONOSTEARATE*
D. K. KITCHEN, M.D., E. W. THOMAS, M.D. AND C. H. REIN, M.D.
In a previous publication (1) we reported results of assays of human sera for
penicillin following the intramuscular injection of a number of repository penicil-
lin products including procaine penicillin (fine particle size) in oil and aluminum
monostearate. That study was suggested by the observation of Buckwalter
and Dickison (2) that vegetable oils gelled with 2% aluminum monostearate
greatly retarded the parenteral absorption of certain drugs suspended in it,
including salts of penicillin.
The purpose of this study was to determine the human serum concentration of
penicillin following the intramuscular injection of this product in five different
schedules of treatment. Three of these (K1, K2, K1) are being used by us in the
treatment of early syphilis. The remaining two schedules (K4, K5) were
effected in order to demonstrate serum concentrations produced by the daily
and every other day intramuscular administration of the product.. The assays
were performed by a cup plate method utilizing sarcina lutea as the test organ-
ism.
Chart P illustrates average serum concentrations following procaine penicillin
(fine particle size) in oil and aluminum monostearate injected in the amounts and
in the manner described. The lines on Chart I are fitted by the method of least
squares to the logarithm of the average blood concentration with time in days.
It is interesting to note that the serum concentration produced and main-
tained by a single injeCtion of eight cc.'s (K2—2.4 million units) is practically
identical with that produced by the injection of this same total amount, but,
when given in two simultaneous injections of 4cc. each in different areas.
Table 1 presents additional data including the number of patients studied on
schedules K1, K2, and K8, the hours at which the blood was assayed, the average
penicillin serum concentration at each of these hours and the percentage of the
total number of patients who maintained a serum concentration of .03 units per
cc. or higher at these hours.
Chart II displays the points of average penicillin serum concentration in
patients receiving the product by the intramuscular route daily (K4) and at
forty-&ght hour intervals (K5). The lines are empirical trends of the direction
of the distribution points. It is evident that when either of these schedules is
followed the blood concentration is definitely cumulative in direct proportion
to the frequency of the administration of the product.
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1 Messrs. Hofstead, McDuffie, Noel and Crutchfield of Bristol Laboratories Inc. made
the statistical analysis of these data.
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* Pretreatment assay for control.
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TABLE 1
6 7 8
ROSIRS
K-i
17 PATIENTS
K-2
19 PATIENTS
K-3
19 PATIENTS
Aver, serum
level
% .03 or
above
Aver. Serum
level
% .03 or
above
Aver. serum
level
0* 0 0 0
1 .57 100 1.045
12 .31 100 .737
24 .24 100 .556
36 .24 100 .508
48 .25 100 .423
72 .23 100 .410
96 .16 94.1 .263
120 .10 94.1 .256
144 .07 52.9 .151
168 .05 41.1 .118
192 .03 35.2 .039
216 .013 17.6
240 .004 5.8
% .03 or
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0
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The distribution points of K represent the lowest blood values during the
treatment period since assays were performed immediately before each twenty-
four hour injection. The distribution points of K5 represent the mid-point in the
blood concentration since in this instance the assays were performed at forty-
eight hour intervals mid-way between injections. A concentration of .03 units
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per cc. or above was maintained on an average of seven days following the last
injection of schedule K4 and five days following the last injection of schedule
K5.
Table 2 presents the number of patients studied in schedules K4 and K5. In
addition, data is given on the average serum concentrations on the days of assay
—
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and the percentage of patients maintaining a serum concentration of .03 or
above on any given day of the observation.
A level of .03 units per cc. of serum is selected, in keeping with standard prac-
tice (3, 4) as representing the theoretical minimum therapeutic concentration.
Speculation as to the relation of penicillin serum concentration and therapeutic
effectiveness is not a part of this presentation.
No instance of undue irritation or untoward effects were reported by, or ob-
served in, patients on any of these five schedules. Several patients on schedule
TABLE 2
R-4 K-5
9 PATIENTS 8 PATIENTS
DAYS
Aver. serum level % .03 or above Aver, serum level % .03 or above
0* 0 0 0 0
1 .100 100 .120 100
2 .170 100 .065 100
3 .191 100 .177 100
4 .208 100 .116 100
5 .251 100 .157 100
6 .307 100 .136 100
7 .317 100 .200 100
8 .311 100 .110 100
9 .304 100 .211 100
10 .283 100 .104 100
11 .361 100 .161 100
12 .395 100 .107 100
13 .347 100 .142 100
14 .348 100 .096 100
1Sf .329 100 .207 100
16 .211 100 .120 100
17 .161 100 .087 87.5
18 .105 77.5 .044 80.0
19 .072 66.6 .030 50.0
20 .051 50.0 0 0
21 .021 42.8
22 .015 50.0
23 0 0
* 0 = Pretreatment assay for control.
f Final Injections.
K2 (8 cc.—one depot) reported moderate pain during, and for a short time fol-
lowing, the injection. Patients on the other schedules had no complaints
whatever.
SUMMARY
Pertinent data is presented on penicillin serum concentrations following the
intramuscular injection of procaine penicillin (fine particle size) in oil with alu-
minum monostearate in five treatment schedules.
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